Foley M, Tilley L
School of Biochemistry, La Trobe University, Victoria, Australia.
Int J Parasitol. 1997 Feb;27(2):231-40. doi: 10.1016/s0020-7519(96)00152-x.
The quinoline-containing antimalarial drugs, chloroquine, quinine and mefloquine, are a vital part of our chemotherapeutic armoury against malaria. These drugs are thought to act by interfering with the digestion of haemoglobin in the blood stages of the malaria life cycle. Chloroquine is a dibasic drug which diffuses down the pH gradient to accumulate about a 1000-fold in the acidic vacuole of the parasite. The high intravacuolar concentration of chloroquine is proposed to inhibit the polymerisation of haem. As a result, the haem which is released during haemoglobin breakdown builds up to poisonous levels, thereby killing the parasite with its own toxic waste. The more lipophilic quinolinemethanol drugs, mefloquine and quinine, are not concentrated so extensively in the food vacuole and probably have alternative sites of action. The technique of photoaffinity labelling has been used to identify a series of proteins which interact specifically with mefloquine. These studies have led us to speculate that the quinolinemethanols bind to high density lipoproteins in the serum and are delivered to the erythrocytes where they interact with an erythrocyte membrane protein, known as stomatin, and are then transferred to the intracellular parasite via a pathway used for the uptake of exogenous phospholipid. The final target(s) of quinine and mefloquine action are not yet fully characterised, but may include parasite proteins with apparent molecular weights of 22 kDa and 36 kDa. As resistance to the quinoline antimalarials rises inexorably, there is an urgent need to understand the molecular basis for decreased drug sensitivity. A parasite-encoded homologue of P-glycoprotein has been implicated in the development of drug resistance, possibly by controlling the level of accumulation of the quinoline-containing drugs. As our molecular understanding of these processes increases, it should be possible to design novel antimalarial strategies which circumvent the problem of drug resistance.
含喹啉的抗疟药物,如氯喹、奎宁和甲氟喹,是我们对抗疟疾化学治疗武器库的重要组成部分。这些药物被认为是通过干扰疟原虫生命周期血液阶段血红蛋白的消化来发挥作用的。氯喹是一种二元碱药物,它沿着pH梯度扩散,在寄生虫的酸性液泡中积累约1000倍。氯喹在液泡内的高浓度被认为可抑制血红素的聚合。结果,血红蛋白分解过程中释放的血红素积累到有毒水平,从而用其自身的有毒废物杀死寄生虫。亲脂性更强的喹啉甲醇类药物,甲氟喹和奎宁,在食物泡中的浓缩程度没有那么高,可能有其他作用位点。光亲和标记技术已被用于鉴定一系列与甲氟喹特异性相互作用的蛋白质。这些研究使我们推测,喹啉甲醇类药物与血清中的高密度脂蛋白结合,并被输送到红细胞,在那里它们与一种称为气孔蛋白的红细胞膜蛋白相互作用,然后通过用于摄取外源性磷脂的途径转移到细胞内寄生虫。奎宁和甲氟喹作用的最终靶点尚未完全明确,但可能包括表观分子量为22 kDa和36 kDa的寄生虫蛋白。随着对喹啉类抗疟药物的耐药性无情上升,迫切需要了解药物敏感性降低的分子基础。一种寄生虫编码的P-糖蛋白同源物与耐药性的发展有关,可能是通过控制含喹啉药物的积累水平。随着我们对这些过程的分子理解不断增加,应该有可能设计出规避耐药性问题的新型抗疟策略。